0001576885-24-000024.txt : 20240119
0001576885-24-000024.hdr.sgml : 20240119
20240119190418
ACCESSION NUMBER: 0001576885-24-000024
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240118
FILED AS OF DATE: 20240119
DATE AS OF CHANGE: 20240119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Barton Russell
CENTRAL INDEX KEY: 0001867418
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40551
FILM NUMBER: 24546774
MAIL ADDRESS:
STREET 1: C/O ACUMEN PHARMACEUTICALS, INC.
STREET 2: 427 PARK STREET
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Acumen Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001576885
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364108129
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 427 PARK ST.
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
BUSINESS PHONE: 925-368-8508
MAIL ADDRESS:
STREET 1: 427 PARK ST.
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
4
1
wk-form4_1705709048.xml
FORM 4
X0508
4
2024-01-18
0
0001576885
Acumen Pharmaceuticals, Inc.
ABOS
0001867418
Barton Russell
C/O ACUMEN PHARMACEUTICALS, INC.
427 PARK STREET
CHARLOTTESVILLE
VA
22902
0
1
0
0
Chief Operating Officer
1
Common Stock
2024-01-18
4
S
0
2833
3.7258
D
96867
D
Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2023.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.7250 to $3.7300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Derek Meisner, Attorney-in-Fact
2024-01-19